Helga Gardarsdottir (H Gardarsdottir)

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 27

Top Topics

Atrial Fibrillation

Venous Thromboembolism

Systematic Review

Electronic Health Record

Top Venues

British journal of clinical pharmacology

Clinical pharmacology and therapeutics

Pharmacoepidemiology and drug safety

This page only lists publications with an associated author ORCID identifier.

Publications

Rosa Gini, Romin Pajouheshnia, Helga Gardarsdottir, Dimitri Bennett, Lin Li, Claudia Gulea, Angelika Wientzek-Fleischmann, Marloes T Bazelier, Mehmet Burcu, Caitlin N Dodd, Carlos E Durán, Sigal Kaplan, Stephan Lanes, Karine Marinier, Giuseppe Roberto, Kanaka Soman, Xiaofeng Zhou, Robert W Platt, Soko Setoguchi, Gillian C Hall
Describing diversity of real world data sources in pharmacoepidemiologic studies: The DIVERSE scoping review. Pharmacoepidemiology and drug safety 33 (5) (2024)
Marieke S Jansen, Olaf M Dekkers, Saskia Le Cessie, Lotty Hooft, Helga Gardarsdottir, Anthonius de Boer, Rolf H H Groenwold
Real-World Evidence to Inform Regulatory Decision Making: A Scoping Review. Clinical pharmacology and therapeutics 115 (6) (2024)
Rosa Gini, Romin Pajouheshnia, Helga Gardarsdottir, Dimitri Bennett, Lin Li, Claudia Gulea, Angelika Wientzek-Fleischmann, Marloes T Bazelier, Mehmet Burcu, Caitlin N Dodd, Carlos E Durán, Sigal Kaplan, Stephan Lanes, Karine Marinier, Giuseppe Roberto, Kanaka Soman, Xiaofeng Zhou, Robert W Platt, Soko Setoguchi, Gillian C Hall
Describing diversity of real world data sources in pharmacoepidemiologic studies: The DIVERSE scoping review. Pharmacoepidemiology and drug safety 33 (5) (2024)
Tessa I van Rijssel, Ghislaine J M W van Thiel, Helga Gardarsdottir, Johannes J M van Delden, null null
Which Benefits Can Justify Risks in Research? The American journal of bioethics : AJOB (2024)
Renske J Grupstra, Thomas Goedecke, Helga Gardarsdottir
Limitations Reported in Evaluating Effectiveness of Risk Minimization Measures in the EU during 2018-2021: A Qualitative Analysis of Industry-Sponsored Post-Authorization Safety Studies. Clinical pharmacology and therapeutics (2024)
Marieke S Jansen, Olaf M Dekkers, Saskia Le Cessie, Lotty Hooft, Helga Gardarsdottir, Anthonius de Boer, Rolf H H Groenwold
Real-World Evidence to Inform Regulatory Decision Making: A Scoping Review. Clinical pharmacology and therapeutics 115 (6) (2024)
Marieke S Jansen, Olaf M Dekkers, Saskia Le Cessie, Lotty Hooft, Helga Gardarsdottir, Anthonius de Boer, Rolf H H Groenwold
Real-World Evidence to Inform Regulatory Decision Making: A Scoping Review. Clinical pharmacology and therapeutics (2024)
Amos J de Jong, Yared Santa-Ana-Tellez, Mira G P Zuidgeest, Renske J Grupstra, Fatemeh Jami, Anthonius de Boer, Helga Gardarsdottir, null null
Direct-to-Participant Investigational Medicinal Product Supply in Clinical Trials in Europe - Exploring the Experiences of Sponsors, Site Staff, and Couriers. British journal of clinical pharmacology (2023)
Sharon C M Essink, Inge M Zomerdijk, Sabine M J M Straus, Helga Gardarsdottir, Marie Louise De Bruin
Duration of Effectiveness Evaluation of Additional Risk Minimisation Measures for Centrally Authorised Medicinal Products in the EU Between 2012 and 2021. Drug safety (2023)
Nicholas B Hunt, Romin Pajouheshnia, Allan Salih, Sander van Doorn, Patrick C Souverein, Marloes T Bazelier, Olaf H Klungel, Helga Gardarsdottir
Full title: Prescribing of Low-dose Rivaroxaban in Patients with Atherosclerotic Cardiovascular Disease in the United Kingdom and the Netherlands. British journal of clinical pharmacology (2023)
Nicholas B Hunt, Romin Pajouheshnia, Allan Salih, Sander van Doorn, Patrick C Souverein, Marloes T Bazelier, Olaf H Klungel, Helga Gardarsdottir
Prescribing of low-dose rivaroxaban in patients with atherosclerotic cardiovascular disease in the United Kingdom and the Netherlands. British journal of clinical pharmacology (2023)
Per Sindahl, Christian Overgaard-Steensen, Helle Wallach-Kildemoes, Marie Louise De Bruin, Kaare Kemp, Helga Gardarsdottir
Impact of a Treatment Guide on Intravenous Fluids in Minimising the Risk of Hospital-Acquired Hyponatraemia in Denmark. Journal of clinical medicine 12 (15) (2023)
Renske J Grupstra, Thomas Goedecke, Jet Scheffers, Valerie Strassman, Helga Gardarsdottir
Review of studies evaluating effectiveness of risk minimisation measures assessed by the European Medicines Agency between 2016 and 2021. Clinical pharmacology and therapeutics (2023)
Tomas Lasys, Yared Santa-Ana-Tellez, Satu J Siiskonen, Rolf H H Groenwold, Helga Gardarsdottir
Unintended impact of pharmacovigilance regulatory interventions: a systematic review. British journal of clinical pharmacology (2023)
Amos J de Jong, Renske J Grupstra, Yared Santa-Ana-Tellez, Mira G P Zuidgeest, Anthonius de Boer, Helga Gardarsdottir, null null
Which decentralised trial activities are reported in clinical trial protocols of drug trials initiated in 2019-2020? A cross-sectional study in ClinicalTrials.gov. BMJ open 12 (8) (2022)
M Mirjam Hempenius, Simone Rijken, Rolf H H Groenwold, Karin Hek, Anthonius de Boer, Olaf H Klungel, Helga Gardarsdottir
Primary nonadherence to drugs prescribed by general practitioners: A Dutch database study. British journal of clinical pharmacology (2022)
Nicholas B Hunt, Helga Gardarsdottir, Marloes T Bazelier, Olaf H Klungel, Romin Pajouheshnia
A systematic review of how missing data are handled and reported in multi-database pharmacoepidemiologic studies. Pharmacoepidemiology and drug safety 30 (7) (2021)
M Mirjam Hempenius, Rolf H H Groenwold, Anthonius de Boer, Olaf H Klungel, Helga Gardarsdottir
Drug exposure misclassification in pharmacoepidemiology: Sources and relative impact. Pharmacoepidemiology and drug safety 30 (12) (2021)
Per Sindahl, Richard Ofori-Asenso, Christine Erikstrup Hallgreen, Kaare Kemp, Helga Gardarsdottir, Marie Louise De Bruin
Impact of regulatory interventions to restrict the combined use of renin-angiotensin system blockers: A Danish nationwide drug utilisation study. British journal of clinical pharmacology (2021)
M Mirjam Hempenius, Rolf H H Groenwold, Patrick C Souverein, Anthonius de Boer, Olaf H Klungel, Helga Gardarsdottir
Impact of anticoagulant exposure misclassification on the bleeding risk of direct oral anticoagulants. British journal of clinical pharmacology 87 (9) (2021)
Ali M Alsamil, Thijs J Giezen, Toine C Egberts, Hubert G Leufkens, Helga Gardarsdottir
Type and Extent of Information on (Potentially Critical) Quality Attributes Described in European Public Assessment Reports for Adalimumab Biosimilars. Pharmaceuticals (Basel, Switzerland) 14 (3) (2021)
Florence P A M van Hunsel, Laura Peters, Helga Gardarsdottir, Agnes Kant
Assessing the Impact on Health of Pharmacovigilance Activities: Example of Four Safety Signals. Drug safety 44 (5) (2021)
Patrick C Souverein, Hendrika A van den Ham, Consuelo Huerta-Álvarez, Elisa Martín Merino, Dolores Montero, Luz M León-Muñoz, Sven Schmiedl, Andreas Heeke, Marietta Rottenkolber, Morten Andersen, Mia Aakjaer, Marie Louise De Bruin, Olaf H Klungel, Helga Gardarsdottir
Comparing risk of major bleeding between users of different oral anticoagulants in patients with nonvalvular atrial fibrillation. British journal of clinical pharmacology 87 (3) (2020)
Yumao Zhang, Patrick C Souverein, Helga Gardarsdottir, Hendrika A van den Ham, Anke-Hilse Maitland-van der Zee, Anthonius de Boer
Risk of major bleeding among users of direct oral anticoagulants combined with interacting drugs: A population-based nested case-control study. British journal of clinical pharmacology 86 (6) (2020)
Florence P A M van Hunsel, Helga Gardarsdottir, Anthonius de Boer, Agnes Kant
Measuring the impact of pharmacovigilance activities, challenging but important. British journal of clinical pharmacology 85 (10) (2019)
Luisa Ibañez, Mònica Sabaté, Xavier Vidal, Elena Ballarin, Marietta Rottenkolber, Sven Schmiedl, Andreas Heeke, Consuelo Huerta-Álvarez, Elisa Martin Merino, Dolores Montero, Luz María Leon-Muñoz, Christiane Gasse, Nicholas Moore, Cécile Droz, Régis Lassalle, Mia Aakjaer, Morten Andersen, Marie Louise De Bruin, Rolf Groenwold, Hendrika A van den Ham, Patrick C Souverein, Olaf Klungel, Helga Gardarsdottir
Incidence of direct oral anticoagulant use in patients with nonvalvular atrial fibrillation and characteristics of users in 6 European countries (2008-2015): A cross-national drug utilization study. British journal of clinical pharmacology 85 (11) (2019)
C L Bekker, B J F van den Bemt, A C G Egberts, M L Bouvy, Helga Gardarsdottir
Patient and medication factors associated with preventable medication waste and possibilities for redispensing. International journal of clinical pharmacy 40 (3) (2018)